Rehda: 77pc of unsold Bumiputera units priced between RM300,000 and RM500,000, high number signals supply-demand mismatch in Malaysian property market
According to the Real Estate and Housing Developers' Association (Rehda), 77 per cent of completed Bumiputera units that remain unsold fall within this price range.
Harian Metro reported that 72 per cent of these units have been on the market for more than 36 months, suggesting a persistent mismatch between supply and demand.
'This issue has become a major challenge for developers and buyers,' Rehda president Datuk Ho Hon Sang said in a statement.
He added that the unsold inventory not only affects developers but also hampers the growth of the national housing sector.
In Rehda's Property Industry Survey for the second half of 2024, 66 out of 177 respondents or 37 per cent said they launched projects in that period, while another 58 respondents (34 per cent) launched theirs in the first half.
Sales performance in the second half of 2024 recorded 3,802 units sold with a take-up rate of 28 per cent, a drop from 47 per cent in the first half.
Of the unsold completed units, 43 per cent were priced between RM400,001 and RM500,000.
Another 11 per cent were homes priced from RM500,001 to RM600,000, followed by 9 per cent above RM1 million.
Homes priced between RM900,000 and RM1 million as well as RM700,001 to RM800,000 accounted for 7 per cent each.
Units under RM100,001 made up 6 per cent of the unsold stock.
Properties priced between RM200,001 and RM300,000, RM100,001 and RM200,000, and RM600,001 to RM700,000 each represented 4 per cent.
Units priced between RM300,001 and RM400,000 made up 3 per cent, while those between RM800,001 and RM900,000 contributed 2 per cent.
For Bumiputera units specifically, 8 per cent of unsold completed homes were priced at RM1 million and above, followed by 7 per cent between RM700,001 and RM1 million.
Another 5 per cent were homes priced below RM300,001, while 3 per cent fell between RM500,001 and RM700,000.
Meanwhile, the National Property Information Centre's (Napic) 2024 Property Market Report revealed there were 23,149 unsold residential units in Malaysia worth an estimated RM13.95 billion.
Homes priced between RM300,000 and RM500,000 accounted for the largest portion of this unsold stock last year.
According to the Valuation and Property Services Department (JPPH), high-rise residential units made up 61.2 per cent or 13,455 units of the unsold homes.
Terraced houses represented 5,187 units or 23.6 per cent, while other property types made up 3,326 units or 15.1 per cent.
Homes aged five to 10 years formed the bulk of the unsold stock at 10,774 units, followed by those under three years at 5,498 units.
Properties aged three to five years recorded 4,726 units, while those over 10 years accounted for 970 units.
For properties under construction, homes priced below RM300,000 made up the largest group of unsold units at 11,562, including 10,864 terraced and high-rise units.
For undeveloped projects, units priced below RM300,000 remained the largest unsold category, with 2,181 terraced units and 1,704 high-rise homes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Charter Communications, Inc. (CHTR) Investors To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Charter Communications, Inc. ('Charter' or the 'Company') (NASDAQ: CHTR) common stock between , inclusive (the 'Class Period'). Charter investors have until October 14, 2025 to file a lead plaintiff motion. What Happened? On July 25, 2025, Charter released its second quarter 2025 financial results, reporting that total internet customers had declined by 117,000, compared to about 100,000 in the second quarter of 2024, when adjusted to remove the prior year's impact of Affordable Connectivity Program ("ACP") related disconnected. The Company's total video customers also decreased by 80,000. On this news, Charter's stock price fell $70.25, or 18.5%, to close at $309.75 per share on July 25, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the impact of the ACP end was a material event the Company was unable to manage or promptly move beyond; (2) the ACP end was actually having a sustaining impact on Internet customer declines and revenue; (3) neither was the Company executing broader operations in a way that would compensate for, or overcome the impact, of the ACP ending; (4) the Internet customer declines and broader failure of Charter's execution strategy created much greater risks on business plans and earnings growth than reported; (5) accordingly, the Company had no reasonable basis to state the Company was successfully executing operations, managing causes of Internet customer declines, or provide overly optimistic statements about the long term trajectory of the Company and EBITDA growth; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Charter common stock during the Class Period, you may move the Court no later than October 14, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
4 hours ago
- Yahoo
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
- In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteoarthritis patients compared with placebo – a substantial, clinically meaningful and statistically significant effect in commonly used Phase III primary endpoints for knee osteoarthritis clinical trials. - Favorable safety profile – No severe adverse events; limited, typically mild to moderate, transient, and treatable side effects occurred in most patients treated with Allocetra™ - Webinar today at 8:00 a.m. Eastern Time Nes-Ziona, Israel, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the 'Company'), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive three-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, 'We are excited to share the topline three-month data from ENX-CL-05-001. We believe these results provide clear indication that Allocetra™ has the potential to become a novel, safe and effective treatment for knee osteoarthritis, a growing market with significant unmet medical need.' The Company will host a webinar today at 8:00 am Eastern Time to provide in-depth analysis of the results. To join the webinar, please click To join the webinar, please register at: It is suggested participants join the webinar at least 15 minutes prior to the scheduled start time to avoid any delays in attendance. About ENX-CL-05-001ENX-CL-05-001 is a multi-center Phase I/II clinical trial consisting of two stages. The first stage was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra™ injections to the target knee, in order to identify the dose and injection regimen for the subsequent Phase IIa stage. The Phase IIa stage is a double-blind, randomized, placebo-controlled multi-centered trial. In addition to evaluating safety, the study protocol was designed to efficiently find a strong signal in a responder population to guide future development, and includes an interim statistical evaluation, conducted by an independent third party and blinded to the Company, to assess the potential value of enrollment of up to 50 patients in addition to the original randomized sample size of 130, and its marginal impact on the p-value of the statistical estimation of the total group and specifically to identify a potential responder sub-group. The trial's key efficacy endpoints evaluate joint-pain and joint-function in comparison to placebo at three months, six months and 12 months post treatment. ABOUT KNEE OSTEOARTHRITIS Osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis is critical. There are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint. ABOUT ENLIVEX Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as 'expects,' 'plans,' 'projects,' 'will,' 'may,' 'anticipates,' 'believes,' 'should,' 'would,' 'could,' 'intends,' 'estimates,' 'suggests,' 'target,' 'has the potential to' and other words of similar meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Therapeutics, INVESTOR RELATIONS CONTACT Dave Gentry, CEORedChip Companies Inc.1-407-644-4256ENLV@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Indianapolis Star
2 days ago
- Indianapolis Star
Boost your productivity with an electric standing desk on sale ahead of Labor Day
After a busy summer full of vacations and perhaps a little more flexibility at work, you might feel the itch to get back into a routine this fall. Giving your office a budget-friendly refresh is one way to set yourself up for success and keep you motivated as we usher in a new season. And, with early Labor Day deals popping up just in time for back-to-school season, it is a great chance to revamp your WFH space. If you want to keep your summer activity levels going, switch to a standing desk such as the popular Vivo Electric Standing Desk (which is currently on sale for under $300) and, while you're at it, add a walking pad to the mix, too! Below, we've highlighted the perks about this Amazon deal on the Vivo Electric Standing Desk, plus a few tips for how to save more at Amazon! The Vivo Electric Standing Desk has more than 5,000 Amazon reviews and more than 1,200 five-star ratings, thanks to its durable construction and versatility. This standing desk is available in a standard 63-inch by 32-inch size (plus eight other sizes ranging from as small as 43 x 24 all the way up to 83 x 30). It also comes in a whopping 40 different finishes, so you can choose the style that best fits your office decor. In addition to its size options and good looks, this desk is designed with all-steel construction with a scratch-resistant carbon fiber surface and can withstand up to 176 pounds on its desktop. And it has a powerful motor that can easily adjust the height from 29 inches up to 48.2 inches for when you need to stretch your legs a bit. Adding to its overall convenience, you don't have to readjust the desk every time you use it. Thanks to its built-in memory controller, you can save four different heights and quickly flip between these settings depending on your needs. Original price: $299.99 | Sale price: 254.99 | Savings: $45 Save 15% at Amazon More: Your Labor Day 2025 shopping guide to the best end-of-summer deals Amazon Prime is a paid membership program that offers various benefits primarily focused on shopping and entertainment. Key perks include free shipping on eligible items, access to streaming content such as Prime Video and Amazon Music. Plus there's exclusive deals and discounts available. More: Is an Amazon Prime membership worth it? Here's what you need to know Currently, new members can try a week of Amazon Prime benefits for just $1.99. After the trial, the membership costs $14.99 per month. Amazon Prime for Young Adults (previously Prime for Students) is a new membership that is focused on perks for young adults between the ages of 18 and 24. Join Prime for Young Adults More: Amazon Prime for Young Adults is back! Do you qualify for the discount? Find out here Prime Access: If you receive SNAP, EBT, Medicaid or other qualifying government aid, you can save with a discounted Prime Access membership.
